Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Codexis, Inc. achieves development milestone in research agreement with Schering-Plough Corporation

DTI Globalwatch : 09 October, 2006  (Company News)
Codexis, Inc., a privately held biotechnology company, announced it has achieved an important development milestone under a research agreement with Schering-Plough Corporation.
The objective of the collaboration with Schering-Plough is to rapidly generate a novel biocatalytic process to produce a key intermediate for an undisclosed human therapeutics compound. This program is based on Codexis' proprietary MolecularBreeding(TM) pharmaceutical process re-engineering platform, and is expected to reduce manufacturing costs and environmental waste in the final production process.

'The agreement with Schering-Plough was announced in March, and Codexis has quickly met the initial development milestone,' said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer. 'We are very pleased with this substantial progress in our collaboration and look forward to continuing to demonstrate the value of our technology to this important partner. An increasing number of worldwide pharmaceutical partners are recognizing the Codexis competitive advantage in developing rapid, efficient clinical-scale manufacturing production processes.'

Codexis' partnerships draw upon the company's expertise and track record in applying its proprietary technology to high-value pharmaceutical products to improve their purity profile and reduce manufacturing time, cost and waste. Codexis has more than 15 partnerships with leading worldwide proprietary and generic pharmaceutical manufacturers.

The company's unique MolecularBreeding(TM) protein and strain engineering technology platform creates superior biological catalysts (biocatalysts), either enzymes or fermentation strains, crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines, dramatically improve existing manufacturing processes and increase chemical development productivity. Codexis estimates that its platform technology can reduce cost of goods by 40 to 70 percent and capital expenditures by over 35 percent. In addition, this platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products.

Codexis' platform technology begins with the selection of genes or genomes with DNA sequence diversity. These gene or genomic variants are then subjected to a proprietary technique that recombines, or 'shuffles,' the DNA. The resulting library encoding for novel biocatalysts is screened for those possessing desirable and improved properties. This process is repeated several times until the resulting enzymes or strains meet or exceed the target performance.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo